Ipca Laboratories has increased its Research and Development (R&D) expenditure to Rs 100.74 crore in FY’13 as compared to Rs 77.96 crore in the previous year. The company has R&D centres at Mumbai, Ratlam, Athal and Indore. The company has set up a new centre at its Mumbai facility for expanding its formulations R&D activities. It is also in the process of setting up a new research centre at Kandivli in Mumbai for bio-tech research & development activities.
Further, the company is also in the process of setting-up a new R&D Centre at Vadodara in Gujarat.
IPCA Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1815.15 |
| Dr. Reddys Lab | 1271.65 |
| Cipla | 1327.50 |
| Zydus Lifesciences | 909.55 |
| Lupin | 2347.85 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: